TiGenix announces private placement

REGULATED INFORMATION 10 DECEMBER 2009

Leuven (BELGIUM) - December 10, 2009 - TiGenix NV (NYSE Euronext Brussels: TIG) announces its intention to raise an indicative amount of EUR 7.5 million in a private placement. The proceeds will be used to fund TiGenix' commercial launch of ChondroCelect and ChondroMimetic and to accelerate the clinical pipeline development.

TiGenix intends to raise an indicative amount of EUR 7.5 million. The new shares will be offered through an accelerated book-build procedure to domestic and foreign qualified professional investors in Belgium and elsewhere in Europe (i.e. the European Economic Area and Switzerland), and will be admitted to trading on Euronext Brussels following their issuance. The offering will start on Thursday December 10th at 8.30 CET.

TiGenix will ask the Banking, Finance and Insurance Commission to suspend its shares from trading on Euronext Brussels. Trading in TiGenix is expected to resume following the publication of the results of the private placement. The Company will announce the results of the private placement as soon as possible after closing of the accelerated book-building procedure. Petercam and ING will be acting as lead managers and joint bookrunners for the offering. KBC will be acting as co-lead manager.

For more information, please contact:
Gil Beyen
Chief Executive Officer

Frank Hazevoets
Chief Financial Officer
T: +32 16 39 60 60
Investor@tigenix.com